CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that it has granted
stock options and restricted stock units to Vivek K. Jayaraman, Cerus’
newly appointed chief commercial officer. These awards were granted
pursuant to the Cerus Corporation Inducement Plan, approved by the
Compensation Committee of Cerus’ Board of Directors and granted as an
inducement material to Mr. Jayaraman’s employment with Cerus, in
accordance with NASDAQ Listing Rule 5635(c)(4).
Cerus granted Mr. Jayaraman an option to purchase 250,000 shares of
Cerus’ common stock with an exercise price of $6.36 per share, the
closing price of Cerus’ common stock on September 1, 2016, the date of
grant. In addition, Cerus granted to Mr. Jayaraman an award in the form
of 75,000 restricted stock units. The shares subject to the option will
vest over a four-year term, with one-eighth of the shares subject to the
option vesting after six months and the remaining shares vesting in
equal monthly increments, and the restricted stock units will vest in
equal annual installments over four years, in each case subject to Mr.
Jayaraman’s continuous service to Cerus on each vesting date.
Cerus is providing this information in accordance with NASDAQ Listing
Rule 5635(c)(4).
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for more information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160907005072/en/
Source: Cerus Corporation